A randomized controlled study comparing intravesical Synergo® System adjuvant hyperthermia treatment in conjunction with Mitomycin C (LHT + MMC) versus BCG intravesical immunotherapy (BCG) adjuvant treatment in patients with Superficial Transitional Cell Carcinoma of the Bladder (STCCB)

Medical Enterprises ongoing clinical study started in 2002. It is a randomized, multi-center study. Urology departments in Hospitals from Italy, France, The Netherlands, Belgium and Israel are participating in the study.

The clinical study Chief investigator is:
Prof J.A Witjes, Department of Urology, Radboud University Hospital, Nijmegen, The Netherlands.

Study Participants:

  • Patients suffering from Superficial Transitional Cell Carcinoma of the Urinary Bladder
    (Ta, T1 or CIS) after tumor removal by Surgery (TUR).
  • Intermediate to high risk for recurrence or progression.
  • No previous intra vesicle instillations of MMC in last 12 months, or BCG in last 24 months
For further information about the clinical study and a list of participating medical centers please contact us.
NIH registered trial;

 
 
Medical Enterprises Europe B.V. Assumburg 152B 1081GC, Amsterdam, The Netherlands Tel: +31 (0) 20 6423719 Fax: +31 (0) 20 6421161
R&D Center: MEL Medical Enterprises Ltd. 6 Odem St. P.O.B. 7166 Petah-Tikva, 49170, ISRAEL Tel: 972 3 9244830 Fax: 972 3 9245340
medical-enterprises.com